These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 19631292)

  • 1. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.
    Sood A; Midha V; Makharia GK; Ahuja V; Singal D; Goswami P; Tandon RK
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1202-9, 1209.e1. PubMed ID: 19631292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
    Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A
    Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
    Tursi A; Brandimarte G; Giorgetti GM; Forti G; Modeo ME; Gigliobianco A
    Med Sci Monit; 2004 Nov; 10(11):PI126-31. PubMed ID: 15507864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy.
    Tsuda Y; Yoshimatsu Y; Aoki H; Nakamura K; Irie M; Fukuda K; Hosoe N; Takada N; Shirai K; Suzuki Y
    Scand J Gastroenterol; 2007 Nov; 42(11):1306-11. PubMed ID: 17852859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis.
    Mardini HE; Grigorian AY
    Inflamm Bowel Dis; 2014 Sep; 20(9):1562-7. PubMed ID: 24918321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis.
    Langmead L; Feakins RM; Goldthorpe S; Holt H; Tsironi E; De Silva A; Jewell DP; Rampton DS
    Aliment Pharmacol Ther; 2004 Apr; 19(7):739-47. PubMed ID: 15043514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis].
    Lee JH; Moon G; Kwon HJ; Jung WJ; Seo PJ; Baec TY; Lee JH; Kim HS
    Korean J Gastroenterol; 2012 Aug; 60(2):94-101. PubMed ID: 22926120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial.
    Tamaki H; Nakase H; Inoue S; Kawanami C; Itani T; Ohana M; Kusaka T; Uose S; Hisatsune H; Tojo M; Noda T; Arasawa S; Izuta M; Kubo A; Ogawa C; Matsunaka T; Shibatouge M
    Dig Endosc; 2016 Jan; 28(1):67-74. PubMed ID: 26418574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.
    Bibiloni R; Fedorak RN; Tannock GW; Madsen KL; Gionchetti P; Campieri M; De Simone C; Sartor RB
    Am J Gastroenterol; 2005 Jul; 100(7):1539-46. PubMed ID: 15984978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
    Kato K; Mizuno S; Umesaki Y; Ishii Y; Sugitani M; Imaoka A; Otsuka M; Hasunuma O; Kurihara R; Iwasaki A; Arakawa Y
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1133-41. PubMed ID: 15569116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
    Shen B; Brzezinski A; Fazio VW; Remzi FH; Achkar JP; Bennett AE; Sherman K; Lashner BA
    Aliment Pharmacol Ther; 2005 Oct; 22(8):721-8. PubMed ID: 16197493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.
    Stremmel W; Merle U; Zahn A; Autschbach F; Hinz U; Ehehalt R
    Gut; 2005 Jul; 54(7):966-71. PubMed ID: 15951544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
    Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
    Schreiber S; Keshavarzian A; Isaacs KL; Schollenberger J; Guzman JP; Orlandi C; Hanauer SB
    Gastroenterology; 2007 Jan; 132(1):76-86. PubMed ID: 17241861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.